Carbamazepine and Cariprazine interaction

Carbamazepine and Cariprazine: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Carbamazepine (EQUETRO) label · effective 2025-08-19

Major

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope.

Drug interactionsby drug classView label on DailyMed
Moderate

Consider reducing the dose of CNS depressants or EQUETRO when using these drugs concomitantly.

Drug interactionsby drug classView label on DailyMed
Minor

Cytochrome (CYP) 3A4 inhibitors, epoxide hydrolase inhibitors, CYP3A4 inducers, drugs metabolized by CYP1A2 or CYP3A4 (oral contraceptives, delavirdine, nefazodone), phenytoin, CNS depressants, lithium, chloroquine, mefloquine ( 7.1 , 7.2 , 7.3 )

Drug interactionsby drug classView label on DailyMed
Minor

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants.

Drug interactionsby drug classView label on DailyMed

From the Cariprazine (Vraylar) label · effective 2025-12-18

Major

Intervention: Concomitant use of VRAYLAR with a CYP3A4 inducer is not recommended [see Dosage and Administration ( 2.1 , 2.6 ) ] .

Drug interactionsby drug classView label on DailyMed
Major

CYP3A4 inducers: Concomitant use is not recommended ( 2.6 , 7 )

Drug interactionsby drug classView label on DailyMed
Minor

CYP3A4 Inducers Clinical Impact: CYP3A4 is responsible for the formation and elimination of the active metabolites of cariprazine.

Drug interactionsby drug classView label on DailyMed
Minor

The effect of CYP3A4 inducers on the exposure of VRAYLAR has not been evaluated, and the net effect is unclear [see Clinical Pharmacology ( 12.3 ) ].

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.